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Abstract
Background: The number of pulmonary tuberculosis (PTB) patients reported with resistance to first-line anti-
tuberculosis drugs after a standardized retreatment regimen in Cameroon is increasing. Hence, the National
Tuberculosis Control Program (NTP) implemented, in one of the ten Regions of the country, a pilot programme
aimed at performing routine drug susceptibility testing (DST) for previously treated PTB cases. The objectives of the
programme were to evaluate the feasibility of monitoring drug resistance among retreatment cases under
programme conditions and to measure the presence and magnitude of anti-TB drug resistance in order to inform
NTP policies.
Findings: This retrospective cohort study was conducted in the Littoral Region of Cameroon in 2009. It included
all sputum smear positive (SM+) PTB cases registered for retreatment. TB cases were identified and classified
according to World Health Organization (WHO) recommendations for national TB programs. Bacterial susceptibility
testing to first-line anti-TB drugs was performed using standard culture methods. In 2009, 5,668 TB cases were
reported in the Littoral Region, of which 438 (7.7%) were SM + PTB retreatment cases. DST results were available
for 216 (49.4%) patients. Twenty six patients (12%) harbored multi-drug resistant (MDR) strains. Positive treatment
outcome rates were particularly low in retreatment patients with MDR-TB (46.2%; 95% CI: 27.1-66.3). Thirteen MDR-
TB patients were treated using a standardized MDR treatment regimen. Delivery of laboratory results took on
average 17 (12-26) weeks.
Conclusions: WHO-recommended routine DST in retreatment patients seems feasible in Cameroon. However,
coverage needs to be improved through better management. Moreover, diagnostic delay should be shortened by
introducing more rapid diagnostic tools. The high risk of MDR in standard regimen failure cases virtually rules out
the standard retreatment regimen for such patients without prior DST.
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Findings
In 2009, about 30,000 or 11% of estimated overall 500, 000
MDR-TB cases were enrolled for second-line treatment.
Achieving universal access to diagnosis and treatment
of multidrug-resistant and extensively drug-resistant tuber-
culosis (M/XDR-TB) remains a challenge [1,2]. According
to WHO, the surveillance and early diagnosis of drug-
resistance in TB is ideally carried out by routine drug-
susceptibility testing (DST) of all TB patients [3]. Where
the circumstances or means do not permit systematic
assessment of all cases with a new episode of TB, alterna-
tively, at least patients known to be at higher risk of carry-
ing drug-resistant strains such as previously treated
patients should be assessed systematically. The Global Plan
to STOP TB (2006-2015) foresees that by 2015 all coun-
tries should carry out DST for all retreatment TB patients
[4].
In Cameroon, in 2009, the estimated TB incidence
rate was 182 cases per 100,000 inhabitants [1]. TB
patients are treated under the National TB Control
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WHO-recommended standard regimens [5]. The total
number of incident MDR-TB cases is estimated to be
440 per year. The cumulative number of MDR-TB
patients put on treatment during the period from Janu-
ary 2005 to December 2008 in either of the two national
MDR-TB treatment centres was 109 [6]. Since 2008,
patients are treated free-of-charge following a standardized
12-month treatment scheme comprising gatifloxacin
(Gfx), clofazimine (Cfz), ethambutol (E), prothionamide
(Pto) and pyrazinamide (Z), administered throughout the
12 months of treatment and supplemented during a mini-
mum four months intensive phase by kanamycin (Km)
and isoniazid (H) (4KmGfxPtoHCfzEZ/8GfxPtoCfzEZ).
Preliminary results of this standardized short-course regi-
men appear to be very promising [7]. Due to the continu-
ous reporting of MDR-TB among previously treated
patients and, in particular, among standard regimen failure
cases, and following the establishment of a supervised
Regional TB Reference Laboratory with culture capacity, a
pilot programme aimed at performing routine DST
among previously treated smear microscopy positive pul-
monary TB (SM + PTB) cases was implemented under
programme conditions in the Littoral Region, one of the
10 Regions of Cameroon. The objectives were to evaluate
the feasibility of monitoring drug resistance among
retreatment cases under programme conditions, measure
the presence and magnitude of drug resistant and particu-
larly MDR-TB in an important subset of retreatment TB
patients in Cameroon and discuss possible implications of
the results for NTP policies.
Materials and methods
Setting and study population
The Littoral Region has about 3.5 million inhabitants, with
some 3 million people living in the economic capital,
Douala. TB cases are reported and virtually treated exclu-
sively within a network of 29 functional government or
private confessional Basic Management Units (BMU). The
number of TB patients treated in the private sector is neg-
ligible as anti-TB drugs are not available, neither in private
pharmacies nor through drug vendors in the informal sec-
tor. Twenty of the BMUs are located in Douala and
receive about 75% of the Littoral Region’s annual incident
cases. More than ninety-five per cent of reported cases ori-
ginate from the Littoral Region. One of the two MDR-TB
treatment centres is situated in Douala. Provider initiated
voluntary counselling and testing for HIV with consequent
Co-trimoxazole prophylaxis is offered free-of-charge to all
newly diagnosed TB-cases. HIV + patients are systemati-
cally referred to the nearest HIV/AIDS treatment service
for further evaluation of their infection.
Inclusion criteria
This study included all consecutively registered SM +
PTB retreatment cases with a new episode of TB
admitted any one the 29 BMUs of the Littoral Region in
Cameroon between 1 January and 31 December 2009
for a standardized retreatment regimen according to
NTP guidelines, categorized as “Relapse”, “Treatment
failure” or “Return after default” (WHO case defini-
tions), and for whom DST results were available [3].
Exclusion criteria
The study excluded all “Other retreatment” cases, i.e.
cases with unknown previous treatment outcome,
patients returning to treatment with smear-negative
PTB or bacteriologically not confirmed extrapulmonary
TB as well as cases with non-tuberculosis mycobacteria.
Transportation of specimen and bacteriological
procedures
TB laboratory technicians in all BMUs had been
instructed to keep one fresh morning sputum specimen
of all consecutively notified SM + PTB retreatment refri-
gerated and to ensure their transportation within 72
hours to the Regional TB Reference Laboratory in
Douala. Here, a new smear was made after decontamina-
tion of the specimens and concentration by centrifuga-
tion. According to routine procedures, two slopes of
Löwenstein-Jensen (LJ) medium per specimen were
inoculated and incubated at 37°C, discarding negative
slopes after ten weeks. Positive cultures were then trans-
ported to the national TB Reference Laboratory, Centre
Pasteur du Cameroun (CPC), for DST using the indirect
proportion method on LJ medium [8]. The following
drugs were tested: rifampicin (R), H, E, streptomycin (S),
Km, and Gfx. - External quality assessment of the Regio-
nal TB Reference Laboratory in Douala is assured
through quarterly supervisions by CPC personnel, and
through continuous feedback on quality of cultures sent
to CPC for DST. The CPC is part of the Supranational
Reference Laboratory Network of the Institute of Tropi-
cal Medicine in Antwerp and is subjected to bi-annual
external quality assessments. - Patients and BMU were
informed about DST test results. A standardized MDR-
TB treatment was proposed to all patients identified with
MDR-TB without clinical improvement under retreat-
ment and still sputum smear positive at their five-month
control.
Ethics
The study protocol was reviewed and approved by the
competent administrative authorities and the National
Ethics Committee of Cameroon.
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TB and demographic data, as well as HIV status, were
extracted from the NTP standard TB registers. TB cul-
ture and DST results (including delivery dates) were
tracked, respectively, through the Regional and National
TB Reference laboratories. Culture and DST results
were matched with patients registered in the BMUs
using the date of registration and the patient’s registra-
tion number. Main outcome measures were the propor-
tion of reported retreatment cases with DST results
available, the proportion of MDR-TB per subcategory of
retreatment cases, and the proportion of retreatment
cases identified with MDR-TB and treatment success
defined as “Cured” or “Treatment completed”. Double
data entry with data cleaning and analysis was done in
Epi Info 6.04 d. Per category data was expressed in per-
centages, continuous variables as mean and standard
variation. All proportions were compared using the c
2
test statistic and Fisher exact test where appropriate.
Results
In 2009, 5,668 TB-cases were reported in the Littoral
Region, of which 528 retreatment cases (9.3%). Of this
number, 438 (83.0%) were SM + PTB retreatment cases
registered in any of the three sub-categories (relapse,
treatment failure, return after default). Where cultures
were negative, failed to grow, were contaminated or
where data were missing, patients were excluded as TB
could not be confirmed. DST results were available for
216 (49.4%) SM + PTB retreatment cases. The selection
of the study population is shown in Figure 1. - The
majority of patients were males (71.3%). Female patients
were significantly younger than male patients (29.9, [SD
+/- 7.5] vs. 38.5 [SD +/- 12.2], respectively; p < 0.001).
HIV infection rate was 25.9% and slightly higher among
female patients. Table 1 presents the sampling coverage
with positive culture and DST results per retreatment
subcategory. The proportions for sampling coverage,
positive culture results and DST results did not differ
significantly between the three subcategories. Equally,
the population with DST results did not differ propor-
tionally from the source population (total of SM + PTB
retreatment patients of the region) in terms of sex and
age distribution.
Table 2 presents the susceptibility patterns related to
retreatment subcategory. A total of 26 (12%) retreatment
cases with DST harbored MDR strains, with an impor-
tant proportion among failure cases (70%; 95% CI: 38.0-
91.7) and a significant proportion among relapse cases
(12%; 95% CI: 7.5-18.4). The proportion of female
patients with MDR-TB was twice that of male patients
(14/62 and 12/154, respectively); OR: 2.35 (1.01-5.48).
Four (15.4%; 95%CI: 5.1-31.1) among the 26 MDR-TB
retreatment cases were HIV positive, of which three
females. Positive sputum control exam results at month 3
were positively associated with MDR-TB (OR: 6.03, 95%
C I :1 . 0 5 - 3 2 . 0 4 ) .H I Vi n f e c t i o n ,h o w e v e r ,w a sn o ts i g n i f i -
cantly associated with MDR-TB disease.
Positive treatment outcome rates did not differ signifi-
cantly between pansusceptible, monoresistant, and polyre-
sistant patients. However, only twelve out of 26 MDR-TB
patients (46.2%; 95% CI: 27.1-66.3) had a successful treat-
ment outcome due to a high failure rate (42.3%; 95% CI:
24.0-62.8) (Table 3). No statistically significant association
was observed between HIV co-infection and unfavorable
treatment outcomes (death, failure, unknown outcome).
Delivery of laboratory results to clinicians took on aver-
age 17 (12-26) weeks. Of the 26 diagnosed MDR-TB cases,
13 patients were treated following the standardized MDR
treatment regimen; three patients died before the start of
MDR-treatment; four patients did not accept another
treatment; four patients remained smear-negative up to
one-year follow-up; two patients were lost to follow-up,
one during retreatment, the other after having being
declared cured.
Discussion
In our retrospective cohort study, 51% of SM + PTB
retreatment patients showed resistance to one or more
anti-TB drugs; those having failed the standard regimen
showed at base-line a high rate of MDR-TB; this rate was
also important in relapse cases. It cannot be excluded that
the relative high failure rate for the retreatment regimen is
partly due to primary MDR-TB with subsequent transmis-
sion. Recently published data from other Regions of
Cameroon suggest an increase in the rate of primary
MDR-TB [9]. As predictable, the proportion of MDR-TB
patients with unfavorable treatment outcome after stan-
dardized chemotherapy, in line with the WHO-recom-
mended retreatment regimen, was unacceptably high.
Finally, the delay between sampling and availability of
laboratory results, 17 weeks on average, was too high for
timely treatment decisions.
The study has several limitations, the most important
of which is possible selection bias with about half of the
cohort excluded due to missing DST results. The incom-
plete coverage of the target population may have dis-
torted the findings. Yet, all BMUs participated in
sampling and the proportion of retreatment subcate-
g o r i e s ,a g ea n ds e xd i s t r i b u t i o n ,a sw e l la st h eH I Vc o -
infection rate in the sampled part of the study population
and the full target population were comparable. - Sec-
ondly, our study was records-based and patients’ classifi-
cation was not controlled. In particular, misclassification
of relapse cases as new cases is common under pro-
gramme conditions; it is possible that the proportion of
relapse cases was underestimated. On the other hand, the
proportion of retreatment cases with their different
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trends observed in the West Region (2004/05, unpub-
lished data), the Littoral Region (2008), and the North-
West Region (2009) [10,11]. - Finally, the exclusion of
DST testing results of smear-negative PTB retreatment
cases in our analysis might have to a certain extent chan-
ged the overall anti-TB drug resistance profile in our
cohort.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SM+ PTB RT 
cases with MDR-
TB 
(n = 26) 
Susceptibilities available 
(n = 216) 
SM+ PTB RT cases with 
culture 
(n = 237) 
SM+ PTB RT cases 
(n = 438) 
SM+ PTB RT cases sampled 
for culture 
 (n = 299) 
Susceptibilities failed to grow (n = 8) 
Susceptibilities missing (n = 6) 
Samples for DST lost (n = 7) 
  RT cases not sampled for culture (n = 139) 
  Inadequate transfer (n = 8)   
  Negative culture result (n = 48) 
  Contaminated (n = 6) 
SM+ PTB RT 
cases pan-
susceptible  
(n = 165) 
SM+ PRB RT cases 
with resistance other 
than HR combination 
(n = 25) 
All RT cases notified 
(n = 528) 
SM- PTB RT cases (n = 76) 
ETB RT cases (n = 13) 
Other RT cases (n = 1) 
Figure 1 Flow chart presenting the study population. (SM+/SM- PTB = smear positive/smear negative pulmonary tuberculosis; DST = drug
susceptibility testing; ETB = extra pulmonary tuberculosis; MDR-TB = multidrug resistant tuberculosis; RT = retreatment).
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country, we did not observe any association between
MDR-TB and HIV [12]. This corroborates the findings
of a recent review which did not find any evidence sup-
porting a systematic association between MDR-TB and
HIV infection across time and geographic locations in
Sub-Saharan African countries [13].
Due to very long turn-around times for DST results (> 4
months) with two different laboratories involved and fre-
quent subculturing needed before obtaining DST results,
the time for initiating MDR-TB treatment in practice coin-
cided with the 5-month control period. For patients with
laboratory-proven MDR-TB but having responded favor-
ably to the standardized retreatment regimen, no MDR
treatment was initiated, thus trading off the benefits of a
MDR-TB treatment against the fact that the standard
retreatment scheme may give positive treatment outcomes
and against the possible side effects of the MDR-TB treat-
ment, in particular a prolonged treatment with potentially
ototoxic aminoglycosides. Indeed, in our cohort, four
(15%; 95% CI: 5-38) MDR-TB patients who were cured
presented no recurrent disease (microscopy and culture
negativity) for up to one year after the end of their retreat-
ment. This clinical (and ethical) decision is debatable [14].
For almost two decades, country and multi-country stu-
dies have gathered overwhelming evidence on unfavorable
outcomes in patients failing the standard regimen, mostly
those infected by MDR-TB and treated according to the
standard WHO-recommended retreatment regimen
[15-20]. Two recent follow-up studies evaluating this regi-
men observed, even after cure, very high rates of recur-
rence in TB patients with MDR-TB at base-line [21,22].
Notwithstanding, most TB programmes in low-income
countries in sub-Saharan Africa treat, empirically, every
year 10-20% of their TB patients using this regimen
[2,15,19]. The design of NTP retreatment regimens
depends on the epidemiological context, the program’s
performance, and the means available. However, MDR-TB
treatment should no longer be a heavily conditioned
option; it is a must, for public health, as well as human
rights reasons [23]. Extrapolating prudently the results of
our study to the rest of the country, a recommendation
for the diagnosis and treatment strategy for retreatment
patients could presently be formulated as follows: 1. Rapid
scaling-up of a well-managed collection and transportation
system in view of systematic DST for at least all failure and
relapse cases [24]; 2. Initiation of standard retreatment
regimen for defaulters and relapse cases, pending DST
results; if results indicate, change to standardized MDR-
TB regimen; 3. Systematic DST for standard regimen fail-
ure cases before initiating treatment, then standardized
retreatment regimen or MDR-TB treatment; in order to
reduce the ‘diagnosis window period’, the NTP should set
up, without delay, newer and more rapid tuberculosis
diagnosis technologies (either line probe assays or Xpert
®
MTB/RIF) at selected strategic sites to enable early detec-
tion of MDR resistance and prioritize high risk patient
groups such as TB patients having failed the standard regi-
men [25].
Conclusion
Preliminary results of systematic DST for SM + PTB
retreatment patients showed that early detection of
MDR-TB under program conditions in Cameroon might
be feasible if more rapid diagnosis tools required for
initiating adequate treatment timely are put in place.
Table 1 DST coverage of reported SM + PTB RT-cases by subcategory in the Littoral Region, 2009
SM + PTB RT-cases, by subcategory Relapse
(n = 286)
n (%)
Treatment failure
(n = 23)
n (%)
Return after default
(n = 129)
n (%)
Total
(n = 438)
n (%)
Sampled for
culture
204 (71.3) 19 (82.6) 83 (64.3) 299 (68.3)
Positive culture 157 (54.9) 11 (47.8) 69 (53.5) 237 (54.1)
DST result 140 (49.0) 10 (43.5) 66 (51.1) 216 (49.3)
Table 2 Susceptibility patterns according to retreatment subcategory in the Littoral Region, 2009
Relapse
(n = 140)
n (%)
Treatment failure
(n = 10)
n (%)
Return after default
(n = 66)
n (%)
Total
(n = 216)
n (%)
Any resistance 34 (24.3) 8 (80.0) 9 (13.6) 51 (23.6)*
Monoresistance 14 (10.0) 0 6 (9.0) 20 (9.3)
Polyresistance
other than MDR
1 (0.7) 1 (10.0) 3 (4.5) 5 (2.3)
MDR-TB 17 (12.1) 7 (70.0) 2 (3.0) 26 (12.0)
￿ P = < 0.001
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men is inadequate in Cameroon for failure cases and
that there is a significant proportion of relapse cases.
Systematic DST for retreatment patients should be
implemented country-wide, while improving access to
rapid diagnosis.
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